IMPLANT FOR INTRAOCULAR DRUG DELIVERY

• US 20090214619A1
• Filed: 03/18/2009
• Published: 08/27/2009
• Est. Priority Date: 11/24/2004
• Status: Abandoned Application

• Current Assignee: The Therakine Corporation
• Original Assignee: The Therakine Corporation
• Inventors: REIFF, Andreas, HAMPTON, Scott, PAYNE, Richard
• Application Number:
  US12/406,876
• Publication Number:
  US 20090214619A1
• Time in Patent Office: Days
• US Class Current: 424/427
• CPC Class Codes: A61F 2210/0004 bioabsorbable
• CPC Class Codes: A61F 2250/0068 the pharmaceutical product being in a reservoir
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61K 31/715 Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: C07K 16/241 Tumor Necrosis Factors

Abstract

An implant for intraocular drug delivery for the treatment of inflammatory or degenerative diseases. In one embodiment, the implant includes a body portion having a first end portion and a second, opposite end portion and defining a cavity with a first opening at the first end portion, and a second, opposite opening at the second end portion, and a solid material received in the cavity, wherein the solid material comprises a depot material and an effective amount of at least one therapeutic compound or agent. When the implant is implanted in an eye of a living subject, the effective amount of at least one therapeutic compound or agent is released to the environment of the implant through at least one of the first opening and the second, opposite opening over an extended period of time.

Claims

1-61. -61. (canceled)

62. A method of treating an inflammatory or degenerative disease in or around the eye, comprising the steps of:

a. providing to the eye an eye implant, the eye implant comprising;

i. an effective amount of at least one therapeutic agent, the at least one therapeutic agent comprising at least one anti-TNFα

antibody, nanobody, antibody fragment, or combination thereof;

anti-interleukine-1 antibody, nanobody, antibody fragment, or combination thereof;

anti-interleukine-6 antibody, nanobody, antibody fragment, or combination thereof;

anti-interleukine-12 antibody, nanobody, antibody fragment, or combination thereof;

or a combination thereof; and

ii. a coating or encapsulating material that coats or encapsulates the at least one therapeutic agent and stabilizes the at least one therapeutic agent;

b. implanting the eye implant in an eye of a living subject, wherein the effective amount of at least one therapeutic agent is releasable to the environment of the eye implant over an extended period of time.

63. The method of claim 62, wherein the flammatory or degenerative disease in or around the eye is uveitis.

64. The method of claim 63, wherein the uveitis is primary uveitis.

65. The method claim 62, wherein the eye implant further comprises a biodegradable or biocompatible material, the coated or encapsulated therapeutic agent being entrapped in the biodegradable or biocompatible material.

66. The method of claim 65, wherein the biodegradable or biocompatible material comprises an inert polymeric material selected from the group of polysulfone, polyetherimide, polyimide, polymethylmethacrylate, siloxanes, polyacrylates, polyetheretherketone, and copolymers thereof.

67. The method of claim 65, wherein the biodegradable material comprises a biodegradable polymeric material selected from modified poly(saccharides), starch, cellulose, chitosan, fibrin, fibronectin, gelatin, collagen, collagenoids, tartrates, gellan gum, dextran, maltodextrin, poly(ethylene glycol), poly(propylene oxide), poly(butylene oxide), Pluoronics, modified polyesters, poly(lactic actid), poly(glycolic acid), poly(lactic-co-glycolic acid), modified alginates, carbopol, poly(N-isopropylacrylamide), poly(lysine), triglyceride, polyanhydrides, poly(ortho)esters, poly(epsilon-caprolactone), poly(butylene terephthalate), polycarbonates, triglyceride, copolymers of glutamic acid and leucine, poly(hydroxyalkanoates) of the PHB-PHV class, proteins, polypeptides, proteoglycans, polyelectolytes, and copolymers and combinations thereof.

68. The method of claim 62, wherein the coating or encapsulating material comprises a polyelectrolyte, a proteoglycan, or both.

69. The method of claim 62, wherein the coating or encapsulating material comprises a proteoglycan.

70. The method of claim 62, wherein the coating or encapsulating material coats the at least one therapeutic agent.

71. The method of claim 62, wherein the at least one therapeutic agent further comprises Interleukine-10, Interleukine-12, or both.

72. The method of claim 62, wherein the second material encapsulates or coats particles of the at least one therapeutic agent.

73. The method of claim 72, wherein particles of the at least one therapeutic agent are coated or encapsulated with a layer-by-layer structure.

74. The method of claim 62, further comprising the step of leaving the eye implant in the eye.